GlassScriptPhysician profile
Paul A Saconn
NPI 1255518734
$819.69
in general payments reported to CMS, 2019-2025
28 companies · $16.80 in 2025
The $16.80 reported for 2025 was less than what a typical Radiation Oncology provider received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $474 · 2020: $219 · 2021: $63.60 · 2023: $46.64 · 2025: $16.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $63.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $63.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tactile Systems Technology INC | $73.17 | 2019 | |
| Novocure INC. | $64.02 | 2020-2021 | |
| Boston Scientific Corporation | $60.22 | 2019 | |
| Novartis Pharmaceuticals Corporation | $59.46 | 2019 | |
| Amgen INC. | $58.29 | 2019-2020 | |
| Janssen Biotech, INC. | $50.11 | 2020-2023 | Erleada, Imbruvica, Darzalex |
| Bayer Healthcare Pharmaceuticals INC. | $41.38 | 2019 | |
| Tesaro, INC. | $36.31 | 2019 | |
| Celgene Corporation | $32.87 | 2019-2020 | |
| Genzyme Corporation | $30.27 | 2019-2020 | |
| Daiichi Sankyo INC. | $28.48 | 2020-2023 | Enhertu |
| Astrazeneca Pharmaceuticals LP | $27.30 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $19.77 | 2019 | |
| Eusa Pharma (US) LLC | $19.57 | 2020 | |
| Dova Pharmaceuticals | $19.07 | 2019 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $18.55 | 2019 | |
| Incyte Corporation | $18.40 | 2020 | |
| Rigel Pharmaceuticals, INC. | $17.56 | 2020 | |
| Pharmacyclics LLC, An Abbvie Company | $17.08 | 2019 | |
| Sumitomo Pharma America, INC. | $16.80 | 2025 | Orgovyx |
| Btg International INC. | $15.14 | 2020 | |
| Secura Bio, INC. | $14.92 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.72 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $13.94 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.88 | 2020 | |
| Blue Earth Diagnostics | $13.18 | 2021 | |
| Seagen INC. | $13.03 | 2019 | |
| Merck Sharp & Dohme LLC | $12.20 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Saconn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.